Israeli healthtech startup IMMA Health has secured a $1.6 million grant from the Israel Innovation Authority while earning the Seal of Excellence from the European Innovation Council. The company is developing the world’s first self-operated transvaginal ultrasound solution for at-home fertility monitoring.
IMMA’s platform combines robotics with artificial intelligence to enable women to perform 3D pelvic ultrasound scans independently from their homes during IVF treatment. The technology aims to reduce the number of clinic visits required for ovarian stimulation monitoring, allowing women to track follicle development independently at home.
The system includes an ultraportable probe designed for manipulation-free use, ultrafast image acquisition technology, and AI-powered automated image analysis that generates standardized reports for physicians. The solution targets the frequent monitoring requirements during IVF cycles, which typically require multiple clinic visits over several weeks.
The funding will support further development of the device and regulatory approval processes. The company is working with medical advisors from leading fertility centers to validate the technology’s clinical effectiveness and integration into existing IVF protocols.
